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James G. Krueger1Psoriasis is present in all racial groups, but in varying frequencies and severity. Considering that small plaque
psoriasis is specific to the Asian population and severe psoriasis is more predominant in the Western popu-
lation, we defined Asian small and intermediate plaque psoriasis as psoriasis subtypes and compared their
molecular signatures with the classic subtype of Western large plaque psoriasis. Two different characteristics of
psoriatic spreading—vertical growth and radial expansion—were contrasted between subtypes, and genomic
data were correlated to histologic and clinical measurements. Compared with Western large plaque psoriasis,
Asian small plaque psoriasis revealed limited psoriasis spreading, but IL-17A and IL-17-regulated proin-
flammatory cytokines were highly expressed. Paradoxically, IL-17A and IL-17-regulated proinflammatory cyto-
kines were lower in Western large plaque psoriasis, whereas T cells and dendritic cells in total psoriatic skin
area were exponentially increased. Negative immune regulators, such as CD69 and FAS, were decreased in both
Western large plaque psoriasis and psoriasis with accompanying arthritis or obesity, and their expression was
correlated with psoriasis severity index. Based on the disease subtype comparisons, we propose that dysre-
gulation of T-cell expansion enabled by downregulation of immune negative regulators is the main mechanism
for development of large plaque psoriasis subtypes.
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Psoriasis is a common skin disease affecting 2% to 3% of the
world population (Koo, 1996a; Stern et al., 2004; van de
Kerkhof, 2008). It begins as a pinhead-sized papule on the
skin that vertically grows to become a raised, red, scaly patch
and radially expands to peripheral body surface area, pro-
gressing eventually to severe cutaneous disease in some
individuals. Severe psoriasis is frequently associated with
systemic inflammation and comorbidities, such as psoriatic
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Ozguven et al., 2000; Gladman et al., 2005; Koo, 1996b;
Neimann et al., 2006; Schon and Boehncke, 2005). Although
high-throughput technologies have enabled us to perform
comprehensive molecular characterization of psoriasis, the
molecular determinants that are proportional to disease
severity and extent are not yet understood. This is, in part,
because psoriasis is a heterogeneous disease caused by
complex interactions between genetic, environmental, and
immunological factors, and none of the preclinical murine
models fully represents the cellular changes and molecular
features of psoriasis (Christophers, 2008; Danilenko, 2008;
Guttman-Yassky et al., 2011; Lowes et al., 2014; Sua´rez-
Farin˜as et al., 2013; Swindell et al., 2011). To overcome this
translational gap and explore potential mechanisms of dis-
ease progression in humans, we identified subtypes of pso-
riasis in which disease progression is limited and contrasted
their cellular and molecular signatures with a more severe
form of psoriasis.
Psoriasis is present in all racial groups, but in varying fre-
quencies and severity. The prevalence is 2.5% in whites,
1.3% in African Americans, but significantly lower in Asians
(0.8% in India, 0.4% in China, and 0.3% in Japan)
(Campalani and Barker, 2005; Gelfand et al., 2005; Prashant,
2010). In Asians, less severe psoriasis is more predominant,
and a distinct phenotype has been particularly reported,
known as “small plaque psoriasis” (Lew et al., 2004; Youn,
2012). Small plaque psoriasis is the typical form of chronicestigative Dermatology. www.jidonline.org 161
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162plaque psoriasis in adults living in Korea and other Asian
countries. This form of psoriasis has some resemblance to
guttate psoriasis but differs in that it is a chronic, stable form
of psoriasis in adults across many years of disease persis-
tence, and overall skin surface involvement is usually <10%
body surface area (see Supplementary Table S1 online).
Considering that small plaque psoriasis is specific to the
Asian population and severe psoriasis is more predominant in
Western population, we compared plaque psoriasis subtypes
between Asian and Western populations to explore possible
disease progression mechanisms. We first subtyped Asian
small and intermediate psoriasis based on the individual
plaque size and the psoriasis area and severity index (PASI).
Then, we confirmed Asian isoforms as true psoriasis subtypes
by identifying a similar transcriptome and histology
compared with moderate-to-severe Western large psoriasis.
We next explored models of disease progression by con-
trasting different cellular and molecular signatures of the
subtypes. The working models represented bidimensional
features of disease progression by separating two different
phases of psoriasis progression: vertical growth (epidermal
hyperplasia) and radial expansion (the extension of overall
psoriasis area and severity). By correlating the genomic data
to the clinical and histologic measurements of disease pro-
gression, we propose that, rather than the increase in driver
cytokines, dysregulation of T-cell expansion enabled by
downregulation of negative regulators is the main mechanismFigure 1. Comparison of epidermal thickness, PASI, differentially expressed gen
small, Asian intermediate, and Western large psoriasis. (a) Asian small psoriasis
Western large psoriasis. (b) Western large psoriasis with higher PASI in compari
diagram comparing DEGs; 27.7% of all DEGs were shared by the three compariso
Affymetrix Human Genome U133 Plus 2.0 Array (meta-analysis-derived transcri
psoriasis transcriptome was differentially expressed in all subtypes (more than tw
Journal of Investigative Dermatology (2016), Volume 136of disease progression to large plaque psoriasis subtypes and
overall disease severity.
RESULTS
Clinical stratification of small and intermediate psoriasis in
the Asian population
We studied 51 biopsy-confirmed psoriasis patients in Seoul,
Korea, where small plaque psoriasis has been previously
reported (Lew et al., 2004). Patients were clinically stratified
into Asian small versus Asian intermediate psoriasis by
considering individual plaque size and disease severity
measured by PASI. Compared with Western large psoriasis,
which has large individual plaque size and typical PASI > 12
(Feldman, 2004; Schmitt and Wozel, 2005), we defined
Asian small and intermediate psoriasis as psoriasis subtypes
with limited disease progression or “mild” disease (see
Supplementary Figure S1 online). Forty-three percent of
patients (22/51) had Asian small psoriasis, in which individual
plaque size (<2 cm) and the extent of psoriasis area and
severity (mean PASI 6.5  0.64) were both limited
(Supplementary Table S1) (Lew et al., 2004). Smaller plaque
size was consistent with thinner epidermal thickness, repre-
senting less epidermal hyperplasia in disease progression
(Figure 1a). Asian small psoriasis also revealed low PASI
(Figure 1b), even when psoriatic plaques were widely distrib-
uted on the trunk and/or extremities (see Supplementary
Figure S2 online).es (DEGs), and meta-analysis-derived psoriasis transcriptome between Asian
with limited epidermal thickness in comparison with Asian intermediate or
son with Asian small or intermediate psoriasis. (c) Area-proportional Venn
n subtypes. (d) DEGs among meta-analysis-derived psoriasis transcriptome for
ptome 3) (Sua´rez-Farin˜as et al., 2012); 66.9% of the meta-analysis-derived
ofold change and <0.05 false discovery rate).
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which individual plaque size (>5 cm) was larger than Asian
small psoriasis (<2 cm), but the extent of psoriasis area
and severity (mean PASI 7.0  0.93) was less than large pso-
riasis (PASI > 12). Psoriatic plaques were localized to the
knees, elbows, scalp, and lower back/buttocks. Otherwise, the
plaques were distributed to limited areas of the trunk or
extremities. Overall, the clinical features of Asian intermedi-
ate psoriasis were similar to mild cases of psoriasis in the
Western population. Clinical photos and immunohistochem-
ical images of 10 representative Asian plaque psoriasis pa-
tients are presented in Supplementary Figure S3 (see online).
Genomic and histologic confirmation of Asian small
and intermediate psoriasis as true psoriasis subtypes
We obtained gene expression profiles with the Affymetrix
Human Genome U133 Plus 2.0 (Affymetrix, Santa Clara, CA)
Array and established the psoriatic transcriptomes of Asian
small, Asian intermediate, and Western large psoriasis by
defining differentially expressed genes between lesional
versus nonlesional skin within each subtype (more than
twofold change, <0.05 false discovery rate). Among 9,637
differentially expressed genes, 2,674 (27.7%) were common
to the three subtypes (Figure 1c). When the gene sets were
narrowed down to a meta-analysis-derived transcriptome of
Western large psoriasis for the identical array (Tian et al.,
2012), there was 66.9% commonality in differentially
expressed genes (Figure 1d).
We next validated if the dysregulation of established pso-
riasis gene sets (Bowcock et al., 2001; Gudjonsson et al.,
2009; Jabbari et al., 2011; Sua´rez-Farin˜as et al., 2010,
2012; Tian et al., 2012; Yao et al., 2008) was equivalently
observed in Asian small and intermediate psoriasis in com-
parison with Western large psoriasis. We performed gene set
variation analysis with the combined z-score method and
generated pathway enrichment scores from the observed
gene expression levels. The analysis revealed that the
enrichment scores of Asian small and intermediate psoriasis
were not different from, or were even higher than, the scores
of Western large psoriasis (P < 0.01 and false discovery rate
< 0.01; see Supplementary Figure S4 online).
Histologic findings in Asian small and intermediate psori-
asis also revealed hallmarks of histologic findings in Western
large psoriasis. In the psoriatic lesional skin of both Asian
small and intermediate psoriasis, the epidermis revealed hy-
perplasia with focal parakeratosis (Supplementary Figure S3,
immunohistochemical images). Key cellular subsets of pso-
riasis immunopathogenesis, CD3þ T cells, and CD11cþ
myeloid dendritic cells accumulated in both subtypes.
Numbers of CD3þ T cells and CD11cþ dendritic cells in
Asian small psoriasis were not different from Western large
psoriasis in slide sections of lesional skin (see Supplementary
Figure S5 online). The number of CD3þ T cells in Asian in-
termediate psoriasis was also not different fromWestern large
psoriasis, whereas CD11cþ dendritic cells were more abun-
dant in Asian intermediate psoriasis compared with Western
large psoriasis. Taken together, Asian small and intermediate
psoriasis phenotypes were validated as psoriasis variants,
sharing a common psoriasis transcriptome and histologic
findings with Western large psoriasis (psoriasis vulgaris).Models of disease progression emerge from subtype
comparisons
We next explored models of disease progression by corre-
lating two different phases of disease progression: vertical
growth (epidermal hyperplasia) measured by epidermal
thickness of lesional skin and radial expansion (the extension
of overall psoriasis area and severity) measured by PASI
(Figure 2). Because Asian small psoriasis was limited in both
epidermal thickness and PASI, we considered it as a model of
the initial stage of disease progression.
To explore mechanisms of vertical growth, we compared
Asian small and intermediate psoriasis, because epidermal
thickness was significantly different between the two sub-
types, without a difference in PASI (Figure 2a). In this model,
CD3þ T cell and CD11cþ dendritic cell infiltrates within the
epidermis and dermal papillary area were significantly
different (see Supplementary Figure S6 online). In addition,
CD3þ T cells and CD11cþ dendritic cells within the
epidermis and dermal papillary area were linearly correlated
with the epidermal thickness (Figure 2b and d; see
Supplementary Table S2 online).
To explore mechanisms of radial expansion, we compared
Asian intermediate and Western large psoriasis, because PASI
was significantly different between the two subtypes, without
a difference in epidermal thickness (Figure 2a). In this model,
the accumulated T-cell and dendritic cell numbers in total
psoriasis body surface area of Western large psoriasis (CD3þ
T cells: 6.24  109  4.68  109; CD11cþ dendritic cells:
5.13  109  4.74  109) were exponentially higher than the
numbers for Asian intermediate psoriasis (CD3þ T cells:
1.18  109  9.76  108; CD11cþ dendritic cells: 1.45 
109  1.43  109) (Supplementary Figure S5). In addition,
CD3þ T cells and CD11cþ dendritic cells in total psoriasis
body surface area were highly correlated to PASI (Figure 2c
and d; Supplementary Table S2).
Genomic exploration of disease progression models
To explore molecular correlates of disease progression, we
simultaneously measured expression levels of 35 genes in
both lesional and nonlesional skin of Asian small (n ¼ 16),
Asian intermediate (n ¼ 21), and Western large (n ¼ 20)
psoriasis by reverse transcriptase (RT) PCR (Figure 3; see
Supplementary Figure S7 online). In the model of the initial
stage of disease progression, IL-17A and IL-17-regulated
proinflammatory cytokines (IL-1B and IL-8) were highly
expressed even before vertical growth and radial expansion.
The expression levels of IL-17A, IL-1B, and IL-8 in RT-PCR
were highest in lesional skin of Asian small psoriasis and
were significantly higher than in Western large psoriasis
(Figure 3a).
In our disease progression model of the vertical growth
phase (Asian small vs. Asian intermediate psoriasis),
epidermal hyperplasia was confirmed by high lesional
expression of keratin 16 in RT-PCR (Figure 3b) and Ki67 in
microarray data (3.9-fold change, P < 0.05, and false dis-
covery rate < 0.05). IL-20, a key molecule for epidermal
hyperplasia response, was expressed higher in Asian inter-
mediate psoriasis in nonlesional skin (Figure 3b). In the
multiple linear regression model predicting epidermal
thickness from the RT-PCR expression levels of 35 psoriaticwww.jidonline.org 163
Figure 2. Exploratory models of disease progression. (a) Vertical growth and radial expansion models emerged from contrasting epidermal thickness and PASI
between Asian small, Asian intermediate, and Western large psoriasis. (b) In the model of vertical growth phase, epidermal thickness was correlated with the
numbers of CD3þ T cells and CD11cþ dendritic cells within the epidermis and dermal papillae (method of counting cells in epidermis and dermal papillae:
Supplementary Figure S6). (c) In the model of radial expansion phase, PASI was correlated with CD3þ T cells and CD11cþ dendritic cells in total psoriasis body
surface area. (d) Summary of exploratory models (r ¼ Pearson correlation, P < 0.0001). Number of inflammatory cells in total psoriasis body surface area ¼ cell
count in the slide section  body surface area  proportion of psoriasis involvement.
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Figure 3. Quantitative comparison of gene expression in psoriatic lesional and nonlesional skin between Asian small (n[ 16), Asian intermediate (n[ 21),
and Western large (n [ 20) psoriasis. Expression levels of genes involved in psoriasis disease progression were quantified by RT-PCR. Gene expression: Log2
conversion of mRNA expression normalized to human acidic ribosomal protein (HARP), *P < 0.05.
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small and intermediate psoriasis in Figure 3 and
Supplementary Figure S7), epidermal thickness of lesional
skin increased in accordance with IL-17A expression in
nonlesional skin (epidermal thicknessLesional ¼ 230.6 þ
34.8  defensin-b103BLesional þ 12.4  IL-17ANonlesional þ
11.7  IFN-aLesional e 35.9  FasLesional, R2 ¼ 0.47, adjusted
R2 ¼ 0.40).In our disease progression model of the radial expansion
phase (Asian intermediate versus Western large psoriasis), we
observed an increase in CD3þ T cells (Figure 2c) and a par-
adoxic decrease in driver cytokines (IL-17A, IL-1B, IL-8, and
IL-20) (Figure 3a and b) in psoriatic lesional skin. We hy-
pothesized that rather than the increase in driver cytokines,
dysregulation of T-cell expansion is the main mechanism of
the radial expansion phase. To explore this hypothesis, wewww.jidonline.org 165
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166first identified significant downregulation of negative regu-
lator signaling in Western large psoriasis in comparison with
Asian intermediate psoriasis (Figure 4a). Among the immune
molecules whose function as a negative regulator have been
described (Abrams et al., 1999; Bovenschen et al., 2011;
Chen et al., 2008; Cortes et al., 2014; Gorbachev and
Fairchild, 2010; Kagen et al., 2006; Sancho et al., 2005;
Stranges et al., 2007; Sugiyama et al., 2005), down-
regulation of CD69, Fas, cytotoxic T lymphocyte-associated
protein 4 (CTLA4), programmed death-ligand 1, and fork-
head box P3 (FoxP3) was confirmed by RT-PCR in lesional
skin of Western large psoriasis in comparison with Asian
small or intermediate psoriasis (Figure 3c). In addition, the
expressions of CD69 (lesional and nonlesional), Fas (lesional
and nonlesional), and CTLA4 (lesional) were negatively
correlated with PASI (Figure 5 and Supplementary Table S2).
Using a multiple regression model to predict PASI from the
RT-PCR expression levels of 35 psoriatic genes in lesional and
nonlesional skin (expressions of Asian intermediate and
Western large psoriasis in Figure 3 and Supplementary
Figure S7), PASI increased in accordance with the reduc-
tion of CD69 expression in nonlesional skin (PASI ¼ e18.2 þ
5.5  tumor necrosis factor [TNF]-aNonlesional þ 3.3 
defensin-b103BNonlesional e 4.1  CD69Nonlesional e 1.2 
IL-9Lesional, R
2 ¼ 0.67, adjusted R2 ¼ 0.63).
Disease progression beyond cutaneous lesions
When comparing comorbid diseases across the psoriasis
variants of Asian small, Asian intermediate, and Western
large psoriasis, there was much more frequent detection of
comorbid conditions with Western large psoriasis. The dif-
ference was statistically significant for body mass index,
psoriatic arthritis, obesity, hypertension, and depression (P <
0.05, see Supplementary Table S3 online). In a subsequent
pairwise comparison with Bonferroni correction, Western
large psoriasis had a higher prevalence of psoriatic arthritis
and obesity than both Asian small and intermediate psoriasis
(P < 0.017). To understand the significant differences in
comorbidities between Asian small or intermediate psoriasis
versus Western large psoriasis, we tested for a difference in
the activation of comorbidity-associated pathways between
the subtypes (Figure 4b). Because conditions comorbid with
psoriasis are often associated with atherosclerosis (Cohen
et al., 2008a; Gladman et al., 2005; Gonzalez-Juanatey
et al., 2007; Neimann et al., 2006; Pyorala et al., 1987),
we selected gene sets of psoriatic arthritis, cardiovascular
disease, and atherosclerosis for comparison. The pathway
analysis revealed that psoriasis comorbidity-related gene sets
were enriched only in Western large psoriasis, whereas there
was no significant enrichment of the same gene sets in Asian
small or intermediate psoriasis (P < 0.001 and false discovery
rate < 0.001) (Lee et al., 2008).
Next, we confirmed clinically the downregulation of
negative regulators contrary to the upregulation of driver
cytokines in the skin of psoriasis patients with accompanying
comorbidities (Figure 6). Compared with psoriasis patients
without psoriatic arthritis, patients with psoriatic arthritis
revealed lower expression levels of negative regulators
(CD69 in lesional skin, FAS in both lesional and nonlesional
skin) in contrast to higher expression levels of driverJournal of Investigative Dermatology (2016), Volume 136cytokines (TNF-a in nonlesional skin, IL-1B in both lesional
and nonlesional skin) (Figure 6a). Similarly, obese psoriasis
patients revealed lower expression levels of negative regu-
lators (CD69 in lesional skin, FAS in both lesional and non-
lesional skin, and FoxP3 in lesional skin) and a higher
expression level of driver cytokine (IL-1B in nonlesional skin)
(Figure 6b).
DISCUSSION
Recent transethnic genome-wide meta-analysis of Asian and
Western psoriasis populations observed the population-
specific effects of the AA positions 114 and 144 of HLA-A
as well as another 10 non-major histocompatibility com-
plex psoriasis susceptibility loci (Yin et al., 2015). These
population-specific risk factors might lead to ethnically
different expression patterns of psoriasis-associated tran-
scriptomes, resulting in different psoriasis prevalence and
clinical phenotypes. In this study, we compared psoriasis
transcriptomes of clinically different Asian and Western
psoriasis cohorts by two independent measures of clinical
phenotyping: epidermal thickness (vertical growth) and PASI
(radial expansion). To understand functional disease status by
molecular characterization, quantitative expression analysis
of RT-PCR (Figure 3 and Supplementary Figure S7) and
pathway analysis of microarray (Figure 4) were combined to
compare against the mRNA transcriptome that has been
established in previous studies (Jabbari et al., 2011; Loscalzo,
2007; Perera et al., 2014; Sua´rez-Farin˜as et al., 2010, 2012).
Serving as a reference list of genes for the core pathogenesis
of psoriasis, we used a meta-analysis-derived transcriptome
built on the same microarray platform (Figure 1d) (Tian et al.,
2012). This approach revealed that IL-17A and IL-17-
regulated proinflammatory cytokines drive disease progres-
sion from the early stage of psoriatic plaque development,
particularly as IL-17 expression was highest in Asian small
psoriasis (Figure 3a). Currently, IL-17-targeted therapies that
neutralize IL-17 (i.e., secukinumab and ixekizumab) have
been studied in phase I to III clinical trials and receive U.S.
Food and Drug Administration approval only for “moderate-
to-severe” psoriasis (typical PASI > 12) (Chiricozzi and
Krueger, 2013). However, Asian forms of psoriasis, which
are classified as “mild” disease (mean PASI < 7) in spite of
significant disease extent, might also benefit from anti-IL-17
agents.
Our study also revealed that nonlesional skin around the
psoriatic plaques is not normal but actively reflects disease
progression status: the epidermal thickness and PASI increase
in accordance with IL-17 and TNF-a in nonlesional skin,
respectively. Also, there was a strong and significant corre-
lation between PASI and negative immune regulatory gene
expressions (CD69 and FAS) in nonlesional skin (Figure 5 and
Supplementary Table S2). Given that excessive immune
activation may be present in nonlesional skin, the expression
of negative immune regulatory pathways may be important in
restraining activation to below-thresholds of producing clin-
ically detectable disease.
The function of negative regulators within lesional and
nonlesional skin is likely important in preventing the disease
progression of psoriasis. In accordance with PASI, CD3þ T
cells were increased in psoriasis body surface area (Figure 2c
Figure 4. Psoriasis pathway enrichment scores. (a) The enrichment of pivotal immune pathways of IL-17 and IFN-g signaling was not different between Asian
small, Asian intermediate, and Western large psoriasis. Negative regulator signaling in Western large psoriasis was downregulated compared with Asian
intermediate psoriasis (*P < 0.01 and false discovery rate < 0.01). (b) Pathways involved in psoriasis comorbidities (psoriatic arthritis, cardiovascular disease,
and atherosclerosis) were significantly enriched only in Western large psoriasis (P < 0.001 and false discovery rate < 0.001). The scores were generated by gene
set variation analysis with the combined z-score method. Gene sets for pathway analysis were curated from published papers (Belasco et al., 2015; Chiricozzi
et al., 2014), molecular signatures database (http://www.broadinstitute.org/gsea/msigdb), and gene ontology consortium (http://geneontology.org).
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Figure 5. Correlation between PASI and expression levels of negative regulators in lesional and nonlesional skin.Overlay scatter-plot to display the correlation
between PASI and expression levels of negative regulators (CD69, FAS, CTLA4, programmed death-ligand 1 [PD-L1], and FoxP3) in lesional (red) and
nonlesional (blue) skin. The expression of TNF-a in lesional and nonlesional skin is presented as a control. Gene expression: Log2 conversion of mRNA
expression normalized to human acidic ribosomal protein (HARP).
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168and Supplementary Table S2), whereas the expression of
negative regulators decreased proportionally (Figure 5 and
Supplementary Table S2). Therefore, we hypothesized that
the lack of negative regulator signals may allow for extensive
expansion of disease-related T-cell clones. In our study, the
expression of FoxP3 in nonlesional skin increased as PASI
increased, but the correlation was not linear (Figure 5 and
Supplementary Table S2). However, the expression of CTLA4,
the inhibitory coreceptor of regulatory T cells (Tregs),
revealed significant linear correlation with PASI in lesional
skin. The expression of the Fas receptor, which is a compo-
nent of the Fas-Fas ligand interactions used by CD4þ CD25þ
Tregs to restrict CD8þ T-cell-mediated immune response in
the skin (Gorbachev and Fairchild, 2010; Stranges et al.,
2007), also revealed significant correlation with PASI in
both lesional and nonlesional skin. Fas is an important
regulator of migratory dendritic cell function and wasJournal of Investigative Dermatology (2016), Volume 136recently identified as central to human skin dendritic cell
programing (Anandasabapathy et al., 2014; Baratin et al.,
2015). Potentially, negative immune regulators such as
CTLA4 and Fas could be more important than classic Tregs in
regulating T-cell expression in psoriasis.
C-type lectin receptor, CD69, exerts a proinflammatory
function in vitro, but recent in vivo studies revealed its
function as an immunoregulatory molecule induced after
activation (Sancho et al., 2005). Because CD69 induction
can block sphingosine 1-phosphate receptor-1-mediated T-
cell egress from lymphoid tissues through interaction with
membrane helix 4, CD69 is demonstrated to be a critical
determinant of prolonged T-cell retention (Bankovich et al.,
2010; Mackay et al., 2015; Shiow et al., 2006). In this
context, downregulation of CD69 in Western large psoriasis
despite an exponentially higher number of CD3þ T cells in
total psoriasis body surface area may represent how T-cell
Figure 6. Downregulation of negative regulators and upregulation of driver cytokines in the skin of psoriasis patients with psoriatic arthritis (a) or obesity (b).
Overlay scatter-plot to display different expression levels of negative regulators (CD69, FAS, and FoxP3) and driver cytokines (tumor necrosis factor [TNF]-a, IL-
1B, and IL-17A) in lesional (red) and non-lesional (blue) skin between psoriasis without (No) and with (Yes) comorbidities. The data include total study
population of Asian small, Asian intermediate, and Western large psoriasis. Gene expression: Log2 conversion of mRNA expression normalized to human acidic
ribosomal protein.
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CD69 could be persistently expressed by a subset of regula-
tory T cells (Sancho et al., 2005). Although CD69þ and
CD69- FoxP3þ Tregs exist in homeostasis, only CD69-
expressing Tregs express high levels of CTLA4 and have
potent suppressor activity secreting high amounts of trans-
forming growth factor-b (Cortes et al., 2014). Considering that
transforming growth factor participates in the differentiationof both Tregs and T helper 17 cells and that Tregs in psoriasis
patients can easily differentiate into IL-17A-producing cells,
CD69 might be the key determinant of disease progression in
psoriasis (Bettelli et al., 2006; Bovenschen et al., 2011;
Cortes et al., 2014; Veldhoen et al., 2006). In our study, the
expression of CD69 in both lesional and nonlesional skin was
highly correlated with PASI in a negative direction (Figure 5
and Supplementary Table S2).www.jidonline.org 169
Figure 7. Molecular determinants of disease progression in psoriasis. Potential molecular determinants of disease progression at different stages were explored
by correlating cellular and molecular signatures to histologic and clinical measurements of disease progression.
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170Taken together, we showed the utility of disease subtype
comparisons with detailed cellular and molecular signa-
tures to advance new hypothesis generation and future
testing of concepts in clinical trials (Figure 7). A limitation
of study is comparing subtypes between distinct ethnic
populations under the assumption that psoriasis tran-
scriptome profiles represent functional disease status
regardless of ethnicity. Ethnicity may confound the corre-
lation between RNA expression of genes involved in pso-
riasis pathogenesis and clinical phenotypes that might be
influenced by other factors, such as genetic/environmental
differences. To overcome this limitation, the concepts
should be further tested in different subtyping strategies and
ultimately in clinical trials blocking driver cytokines and/or
boosting negative regulators in an attempt to prevent dis-
ease progression.
MATERIALS AND METHODS
A detailed Materials and Methods description is available in
Supplementary Materials and Methods (see online).
Study design
This study was designed to conduct ex vivo human observation with
human skin biopsy tissues for the purpose of subtype comparisons
(see Supplementary Figure S8 online). Psoriasis lesional and nonle-
sional skin biopsy tissues were obtained in accordance with the
Helsinki Declaration and approved by the Institutional Review
Board of Korea University Guro Hospital, Seoul, South Korea, and
the Rockefeller University, New York, New York, USA. Written
informed consent was obtained from all patients. Fifty-nine psoriasis
patients were enrolled at Korea University Guro Hospital, and 21
patients were enrolled at the Rockefeller University Hospital
(ClinicalTrials.gov; NCT01920906). Eight patients enrolled in Korea
were excluded because the pathology report from independent
dermatopathologists did not support the diagnosis of psoriasis. Asian
small psoriasis was diagnosed according to the criteria described in
Supplementary Table S1 (Lew et al., 2004). As widely used in ran-
domized clinical trials, Western large psoriasis was defined as
moderate-to-severe psoriasis vulgaris with PASI > 12 (Feldman,
2004; Schmitt and Wozel, 2005).Journal of Investigative Dermatology (2016), Volume 136Three different subtypes (Asian small psoriasis, Asian intermediate
psoriasis, and Western large psoriasis) were compared by clinical
data (demographics and comorbidities), immunohistochemical
analysis, gene expression profiling, and quantitative analysis of gene
expression. For immunohistochemical analysis and gene expression
profiling of Western large psoriasis, we used deidentified repository
data from established cohorts: (i) immunohistochemistry repository
data from tissue bank in the Laboratory for Investigative Derma-
tology at the Rockefeller University, New York (n ¼ 69) and (ii)
National Center for Biotechnology Information Gene Expression
Omnibus repository data (GSE30999, n ¼ 65). Raw microarray data
have been deposited in the National Center for Biotechnology In-
formation’s Gene Expression Omnibus (GSE67853) and are acces-
sible with the following link: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token¼srinkyqcnpupbcf&acc¼GSE67853
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